Holen Sie sich die Stockscreener-App
2.72
1.09%
-0.03
Handel nachbörslich:
2.68
-0.04
-1.47%
Schlusskurs vom Vortag:
$2.75
Offen:
$2.77
24-Stunden-Volumen:
19,009
Relative Volume:
0.19
Marktkapitalisierung:
$85.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.48M
KGV:
-6.9744
EPS:
-0.39
Netto-Cashflow:
$-7.93M
1W Leistung:
+2.26%
1M Leistung:
-10.23%
6M Leistung:
-9.03%
1J Leistung:
-10.82%
1-Tages-Spanne:
$2.61
$2.8596
1-Wochen-Bereich:
$2.55
$2.88
52-Wochen-Spanne:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Vergleichen Sie ANIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.72 | 85.32M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - MarketScreener
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio | ANIX Stock News - GuruFocus
Major Patent Win: Anixa's Revolutionary CAR-T Cancer Treatment Gains Key Protection - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - MarketScreener
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - Yahoo
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th - PR Newswire
Leading Cancer biotech Anixa Biosciences Unveils Latest Innovations at Major Healthcare Conference - Stock Titan
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital - Defense World
What is HC Wainwright’s Forecast for ANIX Q1 Earnings? - Defense World
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines - MarketScreener
Anixa Biosciences Enters Letter of Intent with VERDI Solutions t - GuruFocus
VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines - Nasdaq
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines - Marketscreener.com
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines - Benzinga
Anixa secures US patent for ovarian cancer vaccine tech By Investing.com - Investing.com Australia
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - AOL.com
Anixa secures US patent for ovarian cancer vaccine tech - Investing.com India
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine - Marketscreener.com
Maxim Group Begins Coverage on Anixa Biosciences (NASDAQ:ANIX) - Defense World
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th - Quantisnow
Anixa Biosciences Holds Annual Stockholder Meeting 2025 - TipRanks
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Groundbreaking CAR-T and Cancer Vaccine Updates: Anixa CEO to Present Latest Breakthroughs - StockTitan
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties - BioSpace
Anixa Biosciences Annual Meeting to Feature CEO Update and Investor Q&A - StockTitan
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - Defense World
Anixa Biosciences to Present at the 18th Annual European Life Sc - GuruFocus.com
Anixa Biosciences : to Hold Conference Call to Discuss Outlook for 2019 -January 16, 2019 at 07:31 am EST - MarketScreener
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th - PR Newswire
How Anixa's Revolutionary Ovarian Cancer Therapy Will Take Center Stage at Major Gene Therapy Summit - Stock Titan
Spotlight On February 2025's Promising Penny Stocks - Yahoo Finance
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):